文献速递血栓与止血

华法林治疗患者延长国际标准化比值检测间隔

Extended International Normalized Ratio testing intervals for warfarin-treated patients.
PubMed 文献 · J Thromb Haemost · 2018-06-06

在六家抗凝门诊中,对稳定华法林患者实施延长INR检测间隔(>5周)。符合条件患者中延长检测的使用率从2014年第一季度的41.8%升至2016年第四季度的69.3%。延长检测组的下一次INR超标比例与未延长组相似,临床相关非大出血和急诊就诊率较低。

要点

  • 稳定华法林患者延长INR检测间隔至>5周的使用率从41.8%升至69.3%。
  • 延长检测组与未延长组的下一次INR超标比例相似(27.3% vs 28.4%)。
  • 延长检测组的临床相关非大出血和急诊就诊率低于未延长组。

核心结论

  • 在多样化、基于实践的抗凝门诊中,对稳定华法林患者延长INR检测间隔可以成功且安全地实施。

研究设计与样本

  • 基于实践的多中心协作抗凝门诊实施研究,纳入六家抗凝门诊2014年至2016年间华法林治疗患者。
  • 共识别出3362例华法林治疗患者中890例(26.5%)至少有一个符合延长INR检测条件的时期。

主要发现

  • 符合条件患者中延长INR检测(>5周)的使用率从2014年第一季度的41.8%上升至2016年第四季度的69.3%。
  • 延长检测组与未延长组的下一次INR超标比例相似(27.3% vs 28.4%)。
  • 两组大出血事件数无差异,但延长检测组的临床相关非大出血率(每100患者年0.02 vs 0.09)和急诊就诊率(每100患者年0.07 vs 0.19)低于未延长组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Warfarin typically requires International Normalized Ratio (INR) testing at least every 4 weeks. We implemented extended INR testing for stable warfarin patients in six anticoagulation clinics. Use of extended INR testing increased from 41.8% to 69.3% over the 3 year study. Use of extended INR testing appeared safe and effective. SUMMARY: Background A previous single-center randomized trial suggested that patients with stable International Normalized Ratio (INR) values could safely receive INR testing as infrequently as every 12 weeks. Objective To test the success of implementation of an extended INR testing interval for stable warfarin patients in a practice-based, multicenter collaborative of anticoagulation clinics. Methods At six anticoagulation clinics, patients were identified as being eligible for extended INR testing on the basis of prior INR value stability and minimal warfarin dose changes between 2014 and 2016. We assessed the frequency with which anticoagulation clinic providers recommended an extended INR testing interval (> 5 weeks) to eligible patients. We also explored safety outcomes for eligible patients, including next INR values, bleeding events, and emergency department visits. Results At least one eligible period for extended INR testing was identified in 890 of 3362 (26.5%) warfarin-treated patients. Overall, the use of extended INR testing in eligible patients increased from 41.8% in the first quarter of 2014 to 69.3% in the fourth quarter of 2016. The number of subsequent out-of-range next INR values were similar between eligible patients who did and did not have an extended INR testing interval (27.3% versus 28.4%, respectively). The numbers of major bleeding events were not different between the two groups, but rates of clinically relevant non-major bleeding (0.02 per 100 patient-years versus 0.09 per 100 patient-years) and emergency department visits (0.07 per 100 patient-years versus 0.19 per 100 patient-years) were lower for eligible patients with extended INR testing intervals than for those with non-extended INR testing intervals. Conclusions Extended INR testing for stable warfarin patients can be successfully and safely implemented in diverse, practice-based anticoagulation clinic settings.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Barnes GD, Kong X, Cole D, et al. Extended International Normalized Ratio testing intervals for warfarin-treated patients. J Thromb Haemost. 2018. PMID: 29763979. doi:10.1111/jth.14150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。